https://www.psychiatrist.com/esketamine-ciii-nasal-spray-treatment-resistant-depression/
Information from Industry June 30, 2020
SPRAVATO® (esketamine) CIII Nasal Spray: The First and Only N-Methyl D-Aspartate (NMDA) Receptor Antagonist Approved in Conjunction With an Oral Antidepressant for the Treatment of Adults With Treatment-Resistant Depression
Vol 87 • 2026 • Number 1
Read the Current Issue
Original Research
Innovation in Psychiatric Drug Development: A Quantitative Analysis of FDA-Approved Psychiatric Drugs, 2012–2024
Meta-Analysis
Effectiveness of Peer-Administered Interventions for Perinatal Depression or Anxiety
Original Research
Effect of Adjuvant Metformin on Adherence to and Persistence of Treatment With SGAs in Nondiabetic Patients
Editorial
Thank You to the JCP Community
Editorial
Psychotherapy: Integral to Clinical Psychiatry
Original Research
Trends in Benzodiazepine Prescribing to Adults in the United States
Related Articles
Information from Industry
Auvelity: A Rapid-Acting Antidepressant With Multimodal Activity
September 27, 2024
AUVELITY is an FDA-approved treatment for adults with MDD. Auvelity, is a rapid-acting antidepressant with a multimodal mechanism, targeting both glutamatergic and monoaminergic pathways. Learn more about how AUVELITY...
